Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Edgewise Therapeutics (EWTX) Interest & Investment Income (2020 - 2026)

Edgewise Therapeutics has reported Interest & Investment Income over the past 7 years, most recently at $5.1 million for Q1 2026.

  • Quarterly results put Interest & Investment Income at $5.1 million for Q1 2026, down 1.14% from a year ago — trailing twelve months through Mar 2026 was $23.6 million (down 1.67% YoY), and the annual figure for FY2025 was $23.6 million, down 5.63%.
  • Interest & Investment Income reached $5.1 million in Q1 2026 per EWTX's latest filing, down from $5.8 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $6.6 million in Q2 2024 and bottomed at $166000.0 in Q1 2022.
  • Median Interest & Investment Income over the past 5 years was $5.1 million (2026), compared with a mean of $4.2 million.
  • The largest annual shift saw Interest & Investment Income surged 2014.29% in 2022 before it fell 17.13% in 2025.
  • Over 5 years, Interest & Investment Income stood at $2.7 million in 2022, then surged by 39.6% to $3.7 million in 2023, then surged by 58.05% to $5.9 million in 2024, then fell by 1.96% to $5.8 million in 2025, then dropped by 11.47% to $5.1 million in 2026.
  • Business Quant data shows Interest & Investment Income for EWTX at $5.1 million in Q1 2026, $5.8 million in Q4 2025, and $6.2 million in Q3 2025.